Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 32 | 2024 | 16718 | 1.070 |
Why?
|
HIV-1 | 18 | 2024 | 6939 | 0.820 |
Why?
|
South Africa | 12 | 2023 | 1731 | 0.540 |
Why?
|
HIV | 4 | 2020 | 1604 | 0.450 |
Why?
|
Viral Load | 11 | 2021 | 3299 | 0.430 |
Why?
|
Anti-Retroviral Agents | 6 | 2024 | 1715 | 0.410 |
Why?
|
Vagina | 6 | 2022 | 825 | 0.410 |
Why?
|
Anti-HIV Agents | 3 | 2019 | 4256 | 0.320 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2024 | 2232 | 0.290 |
Why?
|
DNA, Viral | 2 | 2019 | 2225 | 0.260 |
Why?
|
Lactobacillus | 4 | 2022 | 189 | 0.250 |
Why?
|
Genome, Viral | 2 | 2019 | 667 | 0.240 |
Why?
|
Nevirapine | 1 | 2004 | 267 | 0.230 |
Why?
|
Tuberculosis | 3 | 2011 | 1912 | 0.210 |
Why?
|
Viremia | 3 | 2020 | 736 | 0.200 |
Why?
|
Academies and Institutes | 1 | 2023 | 317 | 0.190 |
Why?
|
Vaginosis, Bacterial | 1 | 2022 | 128 | 0.190 |
Why?
|
Antitubercular Agents | 1 | 2007 | 1320 | 0.170 |
Why?
|
Premature Birth | 2 | 2021 | 1721 | 0.170 |
Why?
|
CD8-Positive T-Lymphocytes | 7 | 2023 | 4479 | 0.170 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2021 | 659 | 0.170 |
Why?
|
Focus Groups | 1 | 2023 | 1321 | 0.160 |
Why?
|
Infectious Disease Transmission, Vertical | 2 | 2007 | 1320 | 0.160 |
Why?
|
CD4-Positive T-Lymphocytes | 8 | 2024 | 4386 | 0.160 |
Why?
|
Qualitative Research | 2 | 2023 | 2682 | 0.150 |
Why?
|
Disclosure | 1 | 2023 | 736 | 0.150 |
Why?
|
Host-Pathogen Interactions | 4 | 2021 | 1477 | 0.150 |
Why?
|
Immunity, Humoral | 1 | 2020 | 598 | 0.140 |
Why?
|
Metagenomics | 1 | 2019 | 428 | 0.130 |
Why?
|
Monocytes | 2 | 2021 | 2596 | 0.130 |
Why?
|
Virus Latency | 1 | 2017 | 358 | 0.120 |
Why?
|
Withholding Treatment | 1 | 2019 | 599 | 0.120 |
Why?
|
Public Health | 1 | 2007 | 2603 | 0.120 |
Why?
|
Virus Replication | 2 | 2021 | 2534 | 0.120 |
Why?
|
Sequence Analysis, RNA | 2 | 2020 | 2012 | 0.120 |
Why?
|
Contraceptive Agents, Female | 1 | 2015 | 135 | 0.120 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2007 | 2026 | 0.120 |
Why?
|
Immunity, Cellular | 1 | 2020 | 1607 | 0.120 |
Why?
|
Antigens, CD | 2 | 2021 | 4026 | 0.120 |
Why?
|
Progestins | 1 | 2015 | 306 | 0.120 |
Why?
|
HIV Antibodies | 1 | 2020 | 1322 | 0.110 |
Why?
|
Cervix Uteri | 1 | 2017 | 590 | 0.110 |
Why?
|
Interferon-gamma | 3 | 2019 | 3206 | 0.110 |
Why?
|
Cell Communication | 1 | 2020 | 1621 | 0.110 |
Why?
|
Th1 Cells | 1 | 2017 | 1057 | 0.100 |
Why?
|
Cytokines | 3 | 2021 | 7322 | 0.090 |
Why?
|
Evolution, Molecular | 1 | 2019 | 1940 | 0.090 |
Why?
|
Dendritic Cells | 1 | 2021 | 2725 | 0.090 |
Why?
|
Humans | 39 | 2024 | 744343 | 0.090 |
Why?
|
Female | 24 | 2024 | 380194 | 0.090 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 2 | 2008 | 222 | 0.090 |
Why?
|
Young Adult | 11 | 2021 | 56430 | 0.090 |
Why?
|
Immunoglobulin G | 1 | 2021 | 4560 | 0.090 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2183 | 0.090 |
Why?
|
Lymphocyte Activation | 2 | 2020 | 5524 | 0.080 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2009 | 224 | 0.080 |
Why?
|
Acute Disease | 4 | 2020 | 7149 | 0.080 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 3647 | 0.080 |
Why?
|
Lymphocytes | 1 | 2016 | 2617 | 0.080 |
Why?
|
DNA Methylation | 1 | 2021 | 4286 | 0.070 |
Why?
|
Poverty | 1 | 2018 | 2660 | 0.070 |
Why?
|
Intestines | 1 | 2016 | 1924 | 0.070 |
Why?
|
Public Sector | 1 | 2007 | 265 | 0.070 |
Why?
|
Longitudinal Studies | 5 | 2021 | 13989 | 0.070 |
Why?
|
Socioeconomic Factors | 2 | 2017 | 7785 | 0.070 |
Why?
|
Transcriptional Activation | 2 | 2023 | 1783 | 0.060 |
Why?
|
Health Plan Implementation | 1 | 2007 | 352 | 0.060 |
Why?
|
Self Care | 1 | 2009 | 786 | 0.060 |
Why?
|
HLA Antigens | 1 | 2009 | 1381 | 0.060 |
Why?
|
Leukocytes, Mononuclear | 2 | 2021 | 1836 | 0.060 |
Why?
|
HIV Long Terminal Repeat | 1 | 2023 | 88 | 0.060 |
Why?
|
Health Resources | 1 | 2009 | 911 | 0.060 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 1 | 2023 | 127 | 0.060 |
Why?
|
Empirical Research | 1 | 2023 | 120 | 0.060 |
Why?
|
Dipeptidyl Peptidase 4 | 1 | 2022 | 91 | 0.050 |
Why?
|
Receptors, CXCR5 | 1 | 2022 | 92 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2019 | 10180 | 0.050 |
Why?
|
Infant, Newborn | 5 | 2021 | 25625 | 0.050 |
Why?
|
CD4 Lymphocyte Count | 3 | 2015 | 2559 | 0.050 |
Why?
|
Prospective Studies | 4 | 2019 | 53288 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 2020 | 2133 | 0.050 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2023 | 442 | 0.050 |
Why?
|
Male | 9 | 2023 | 350118 | 0.050 |
Why?
|
Genes, Immunoglobulin | 1 | 2021 | 291 | 0.050 |
Why?
|
Metronidazole | 1 | 2022 | 217 | 0.050 |
Why?
|
Lymph Nodes | 2 | 2022 | 3474 | 0.050 |
Why?
|
HIV Core Protein p24 | 1 | 2020 | 256 | 0.050 |
Why?
|
Adolescent | 8 | 2021 | 85781 | 0.050 |
Why?
|
Acute-Phase Reaction | 1 | 2020 | 91 | 0.050 |
Why?
|
GPI-Linked Proteins | 1 | 2021 | 434 | 0.040 |
Why?
|
Germinal Center | 1 | 2022 | 377 | 0.040 |
Why?
|
Clone Cells | 1 | 2023 | 1692 | 0.040 |
Why?
|
Phenotype | 3 | 2023 | 16365 | 0.040 |
Why?
|
Interleukin-7 Receptor alpha Subunit | 1 | 2019 | 52 | 0.040 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2021 | 906 | 0.040 |
Why?
|
T-Lymphocyte Subsets | 1 | 2007 | 1838 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2007 | 1873 | 0.040 |
Why?
|
RNA, Viral | 2 | 2019 | 2902 | 0.040 |
Why?
|
HIV Envelope Protein gp41 | 1 | 2020 | 314 | 0.040 |
Why?
|
Gender Identity | 1 | 2024 | 688 | 0.040 |
Why?
|
Antibody Specificity | 1 | 2020 | 1095 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2021 | 588 | 0.040 |
Why?
|
Pregnancy | 4 | 2021 | 29144 | 0.040 |
Why?
|
Systems Integration | 1 | 2020 | 440 | 0.040 |
Why?
|
Antigen-Presenting Cells | 1 | 2021 | 973 | 0.040 |
Why?
|
Violence | 1 | 2024 | 909 | 0.040 |
Why?
|
Cysteine | 1 | 2022 | 874 | 0.040 |
Why?
|
Glycosylation | 1 | 2020 | 1126 | 0.040 |
Why?
|
Complement System Proteins | 1 | 2020 | 795 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 4751 | 0.040 |
Why?
|
Prevotella | 1 | 2017 | 79 | 0.040 |
Why?
|
Bacteria, Anaerobic | 1 | 2017 | 68 | 0.040 |
Why?
|
Time Factors | 4 | 2021 | 40075 | 0.040 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2023 | 4420 | 0.030 |
Why?
|
Cells, Cultured | 3 | 2021 | 19229 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2019 | 3597 | 0.030 |
Why?
|
HIV Envelope Protein gp120 | 1 | 2020 | 952 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2017 | 5974 | 0.030 |
Why?
|
Antigens, Viral | 1 | 2019 | 1035 | 0.030 |
Why?
|
Phagocytosis | 1 | 2020 | 1539 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2010 | 7913 | 0.030 |
Why?
|
Sequence Analysis | 1 | 2015 | 256 | 0.030 |
Why?
|
Women's Health | 1 | 2024 | 2034 | 0.030 |
Why?
|
Cohort Studies | 4 | 2018 | 40561 | 0.030 |
Why?
|
Peer Group | 1 | 2018 | 635 | 0.030 |
Why?
|
Africa | 1 | 2015 | 673 | 0.030 |
Why?
|
Injections | 1 | 2015 | 840 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2020 | 1821 | 0.030 |
Why?
|
Biodiversity | 1 | 2015 | 341 | 0.030 |
Why?
|
Immunologic Memory | 1 | 2019 | 1348 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2009 | 5137 | 0.030 |
Why?
|
Protein Processing, Post-Translational | 1 | 2020 | 1990 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2010 | 7181 | 0.030 |
Why?
|
Contraception | 1 | 2015 | 359 | 0.030 |
Why?
|
Glucose | 1 | 2024 | 4397 | 0.030 |
Why?
|
Health Education | 1 | 2018 | 1056 | 0.030 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2015 | 954 | 0.020 |
Why?
|
Adult | 7 | 2020 | 214055 | 0.020 |
Why?
|
Phylogeny | 1 | 2019 | 2803 | 0.020 |
Why?
|
Biopsy | 1 | 2023 | 6756 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2020 | 1708 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2021 | 4328 | 0.020 |
Why?
|
Therapeutic Equipoise | 1 | 2010 | 28 | 0.020 |
Why?
|
Alleles | 1 | 2021 | 6933 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2019 | 4186 | 0.020 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2010 | 66 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 25043 | 0.020 |
Why?
|
Laboratories, Hospital | 1 | 2011 | 194 | 0.020 |
Why?
|
Prognosis | 2 | 2021 | 29063 | 0.020 |
Why?
|
Sputum | 1 | 2011 | 476 | 0.020 |
Why?
|
Apoptosis | 2 | 2016 | 9727 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2004 | 14722 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2023 | 7722 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2019 | 6489 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2019 | 10481 | 0.020 |
Why?
|
Gene Products, gag | 1 | 2009 | 337 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2022 | 2988 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2022 | 4665 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 1434 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8324 | 0.020 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 1 | 2007 | 39 | 0.020 |
Why?
|
HLA-B Antigens | 1 | 2009 | 353 | 0.020 |
Why?
|
Genetic Variation | 1 | 2023 | 6544 | 0.020 |
Why?
|
Kinetics | 1 | 2015 | 6473 | 0.020 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 1 | 2007 | 153 | 0.020 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2010 | 657 | 0.020 |
Why?
|
Clinical Laboratory Techniques | 1 | 2011 | 738 | 0.020 |
Why?
|
Africa South of the Sahara | 1 | 2007 | 724 | 0.020 |
Why?
|
Bacteria | 1 | 2015 | 2114 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2016 | 2958 | 0.010 |
Why?
|
Interferons | 1 | 2007 | 706 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9438 | 0.010 |
Why?
|
Cell Movement | 1 | 2016 | 5217 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2016 | 2987 | 0.010 |
Why?
|
Risk | 1 | 2015 | 9687 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2021 | 21746 | 0.010 |
Why?
|
Epitopes | 1 | 2009 | 2571 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2021 | 63114 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2010 | 4933 | 0.010 |
Why?
|
Infant | 3 | 2009 | 35136 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2019 | 11483 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10638 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2015 | 12354 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2008 | 1904 | 0.010 |
Why?
|
Chronic Disease | 1 | 2016 | 9146 | 0.010 |
Why?
|
Developing Countries | 1 | 2011 | 2815 | 0.010 |
Why?
|
Mothers | 1 | 2009 | 2165 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39050 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2016 | 12072 | 0.010 |
Why?
|
Incidence | 1 | 2015 | 20947 | 0.010 |
Why?
|
Sex Factors | 1 | 2009 | 10397 | 0.010 |
Why?
|
United States | 1 | 2023 | 69872 | 0.010 |
Why?
|
Mutation | 1 | 2019 | 29786 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2011 | 5319 | 0.010 |
Why?
|
Disease Progression | 1 | 2009 | 13284 | 0.010 |
Why?
|
Animals | 2 | 2017 | 168757 | 0.010 |
Why?
|
Mice | 1 | 2017 | 81183 | 0.010 |
Why?
|
Child | 1 | 2011 | 77709 | 0.000 |
Why?
|
Middle Aged | 1 | 2017 | 213383 | 0.000 |
Why?
|
Concepts
(199)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(39)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_